Moderna and Merck reported positive Phase 3 trial results for their personalized mRNA-based cancer vaccine combined with Keytruda, showing significant improvement in recurrence-free survival for melanoma patients. This marks the first successful Phase 3 study of an individualized mRNA cancer therapy, potentially expanding Moderna's business beyond COVID-19 vaccines. The companies plan to present detailed data and pursue regulatory approval, possibly by 2027, boosting investor confidence and Moderna's oncology pipeline prospects.
Moderna's stock surged 5% to $181.51, marking a 516% gain in 2026, driven by anticipation of late-October Phase 3 data for its personalized cancer therapy, intismeran autogene, developed with Merck. The therapy targets high-risk melanoma patients and...
Moderna's shares surged 9% after its Phase 3 melanoma study was selected for a prestigious Presidential Symposium slot at the European Society for Medical Oncology congress. This high-profile placement signals strong confidence in the study's potenti...
